|
Name |
Xanthoquinodin A3
|
Molecular Formula | C31H24O11 | |
IUPAC Name* |
methyl (1R,7R,13S)-11,16,18-trihydroxy-20-methyl-9,14,23-trioxo-7-[(2S)-5-oxooxolan-2-yl]-6-oxahexacyclo[11.10.2.01,15.03,12.05,10.017,22]pentacosa-3,5(10),11,15,17(22),18,20,24-octaene-7-carboxylate
|
|
SMILES |
CC1=CC2=C(C(=C1)O)C(=C3C(=O)[C@H]4C=C[C@]3(C2=O)CC5=CC6=C(C(=O)C[C@@](O6)([C@@H]7CCC(=O)O7)C(=O)OC)C(=C45)O)O
|
|
InChI |
InChI=1S/C31H24O11/c1-12-7-15-22(16(32)8-12)27(37)24-25(35)14-5-6-30(24,28(15)38)10-13-9-18-23(26(36)21(13)14)17(33)11-31(42-18,29(39)40-2)19-3-4-20(34)41-19/h5-9,14,19,32,36-37H,3-4,10-11H2,1-2H3/t14-,19-,30-,31+/m0/s1
|
|
InChIKey |
JUSHCXMJWBJGNO-CLEZSSNSSA-N
|
|
Synonyms |
Xanthoquinodin A3; Xanthoquinodin A3_130145; CHEMBL2333573
|
|
CAS | NA | |
PubChem CID | 71720663 | |
ChEMBL ID | CHEMBL2333573 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 572.5 | ALogp: | 3.1 |
HBD: | 3 | HBA: | 11 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 174.0 | Aromatic Rings: | 8 |
Heavy Atoms: | 42 | QED Weighted: | 0.353 |
Caco-2 Permeability: | -5.234 | MDCK Permeability: | 0.00001930 |
Pgp-inhibitor: | 0.148 | Pgp-substrate: | 0.011 |
Human Intestinal Absorption (HIA): | 0.192 | 20% Bioavailability (F20%): | 0.02 |
30% Bioavailability (F30%): | 0.916 |
Blood-Brain-Barrier Penetration (BBB): | 0.024 | Plasma Protein Binding (PPB): | 80.94% |
Volume Distribution (VD): | 0.582 | Fu: | 8.48% |
CYP1A2-inhibitor: | 0.641 | CYP1A2-substrate: | 0.446 |
CYP2C19-inhibitor: | 0.148 | CYP2C19-substrate: | 0.063 |
CYP2C9-inhibitor: | 0.497 | CYP2C9-substrate: | 0.311 |
CYP2D6-inhibitor: | 0.426 | CYP2D6-substrate: | 0.114 |
CYP3A4-inhibitor: | 0.787 | CYP3A4-substrate: | 0.213 |
Clearance (CL): | 2.16 | Half-life (T1/2): | 0.062 |
hERG Blockers: | 0.03 | Human Hepatotoxicity (H-HT): | 0.168 |
Drug-inuced Liver Injury (DILI): | 0.938 | AMES Toxicity: | 0.198 |
Rat Oral Acute Toxicity: | 0.758 | Maximum Recommended Daily Dose: | 0.894 |
Skin Sensitization: | 0.31 | Carcinogencity: | 0.792 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
Respiratory Toxicity: | 0.12 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002421 | 0.711 | D07MGA | 0.255 | ||||
ENC006102 | 0.638 | D01XDL | 0.251 | ||||
ENC006113 | 0.473 | D01XWG | 0.251 | ||||
ENC006114 | 0.416 | D07VLY | 0.247 | ||||
ENC003348 | 0.401 | D0C9XJ | 0.247 | ||||
ENC005885 | 0.377 | D0T8EH | 0.242 | ||||
ENC005733 | 0.367 | D01UBX | 0.239 | ||||
ENC002486 | 0.358 | D0H1AR | 0.235 | ||||
ENC005734 | 0.350 | D0FX2Q | 0.233 | ||||
ENC002742 | 0.346 | D03RTK | 0.230 |